You are here:

Douglas Grossman

Professor of Dermatology and
Adjunct Professor of Oncological Sciences

Grossman Photo

B.S. Duke University

Ph.D. Baylor College of Medicine

M.D. Baylor College of Medicine

Research

References

doug.grossman@hci.utah.edu

Doug Grossman's Lab Page

Doug Grossman's PubMed Literature Search

Molecular Biology Program

Skin Cancer, chemoprevention, Survivin, p16

Research

My research interests are focused on melanoma, the most serious form of skin cancer, which arises from melanocytes or nevi (moles). Our current work spans a spectrum from basic science (mechanisms of melanoma development and metastasis) to translational (melanoma chemoprevention) to clinical research (early melanoma detection).  As a physician-scientist, I devote 75% of my effort to research and 25% of my effort to patient care (as Director of the Early Melanoma Detection clinic at HCI).

Ongoing projects

  1. Role of p16 and oxidative stress in melanoma.  The CDKN2A (p16) gene is frequently mutated in families with melanoma predisposition, and suppressed by methylation or deleted in melanoma tumors. It is thought to function as a tumor suppressor by slowing the cell cycle and inducing senescence.  We have reported an alternate function – regulation of oxidative stress, as its depletion from cells results in increased levels of reactive oxygen species without affecting the cell cycle. We recently showed that the increased ROS in cells lacking p16 results from an imbalance of increased mitochondrial biogenesis and impaired respiration.  We are currently analyzing the effects of familial melanoma-associated mutations in p16 on these various activities.
  2. New agents for melanoma chemoprevention.  We have previously worked with N-acetylcysteine (NAC) as an oral preventive agent for patients at risk for melanoma. We completed a phase II trial to test whether NAC can protect nevi from UV-induced oxidative damage which we have shown in a mouse model is important for melanoma development.  Current research in this area is focused on aspirin, studying its metabolism in humans and mice, and its potential as a melanoma preventive agent using cellular, mouse, and human systems.
  3. Methods of early melanoma detection.  We are using total body photography to monitor our patients who are at increased risk of melanoma, and have studied the role of photography in the physician decision to biopsy and early detection of melanoma.  Current research in this area involves studying the survival outcomes of 3000 patients who have been monitored by photography over the past 13 years.

References

Selected Recent Publications

  1. Tyagi E, Liu B, Li C, Liu T, Rutter J, Grossman D (2017): Loss of p16INK4A stimulates aberrant mitochondrial biogenesis through a CDK4/Rb-independent pathway.  Oncotarget, in press.
  2. Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D: Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res, in press.
  3. Cassidy P, Liu T, Florell SR, Honeggar M, Leachman SA, Boucher KM, Grossman D (2017): A phase II randomized placebo-controlled trial of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress in vivo.  Cancer Prev Res (Phila) 10:36–44.
  4. Truong A, Strazzulla L, March J, Boucher KM, Nelson KC, Kim CC, Grossman D (2016): Reduction in nevus biopsy rates in patients monitored by total body photography.  J Am Acad Dermatol 75:135-143.  
  5. Jenkins NC, Jung J, Liu T, Wilde M, Holmen SL, Grossman D (2013): Familial melanoma-associated mutations in p16 uncouple its tumor suppressor functions. J Invest Dermatol 133:1043-1051

to page top

Last Updated: 8/11/17